» Articles » PMID: 34292559

Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes

Overview
Journal Diabetes Ther
Date 2021 Jul 22
PMID 34292559
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Lipid-lowering therapy (LLT) reduces the risk of cardiovascular disease (CVD) in patients with type 1 diabetes (T1D). However, socioeconomic factors and gender may have an impact on the adherence to and non-persistence with LLT.

Methods: This was a nationwide register-based cohort study that included 6192 individuals with T1D aged ≥ 18 years who were registered in the Swedish National Diabetes Register and had initiated novel use of LLT. Information on socioeconomic parameters (source: Statistics Sweden) and comorbidity (source: National Patient Register) was collected. The individuals were followed for 36 months, and adherence to LLT was analyzed according to age, socioeconomics and gender. The medication possession ratio (MPR; categorized into ≤ 80% and > 80%) and non-persistence (discontinuation) with medication was calculated after 18 and 36 months.

Results: Individuals older than 53 years were more adherent to LLT (MPR > 80%) than those younger than 36 years (odds ratio [(OR] 1.30, p < 0.0001) at 36 months. Women were more adherent and less prone to discontinue LLT at 18 months (OR 1.05, p = 0.0005 and OR 0.95, p = 0.0004, respectively), but not at 36 months. Divorced individuals were less adherent than married ones (OR 0.93, p = 0.0005) and discontinued LLT more often than the latter (OR 1.06, p = 0.003). Education had no impact on adherence, but individuals with higher incomes discontinued LLT less frequently than those with lower incomes. Individuals with a country of origin other than Sweden discontinued LLT more often.

Conclusion: Lower adherence to LLT in individuals with T1D was associated with male gender, younger age, marital status and country of birth. These factors should be considered when evaluating adherence to LLT in clinical practice, with the aim to help patients achieve full cardioprotective treatment.

Citing Articles

Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients.

Wawruch M, Petrova M, Celovska D, Alfian S, Tesar T, Murin J Front Pharmacol. 2025; 15:1464689.

PMID: 39744138 PMC: 11688177. DOI: 10.3389/fphar.2024.1464689.


Social and Structural Determinants of Cardiovascular Complications of Diabetes.

Mensah P, Valdez K, Gyawali A, Snell-Bergeon J Curr Diab Rep. 2024; 24(7):147-157.

PMID: 38696042 DOI: 10.1007/s11892-024-01541-7.


The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology.

Virani S, Aspry K, Dixon D, Ferdinand K, Heidenreich P, Jackson E Am J Prev Cardiol. 2023; 13:100472.

PMID: 36970638 PMC: 10037190. DOI: 10.1016/j.ajpc.2023.100472.


Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts.

Zaharia O, Lanzinger S, Rosenbauer J, Karges W, Mussig K, Meyhofer S Front Endocrinol (Lausanne). 2022; 13:760778.

PMID: 35721726 PMC: 9205191. DOI: 10.3389/fendo.2022.760778.


Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy.

Degli Esposti L, Veronesi C, Ancona D, Andretta M, Bartolini F, Drei A Clinicoecon Outcomes Res. 2022; 14:139-147.

PMID: 35299992 PMC: 8922236. DOI: 10.2147/CEOR.S345852.

References
1.
Vrijens B, de Geest S, Hughes D, Przemyslaw K, Demonceau J, Ruppar T . A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5):691-705. PMC: 3403197. DOI: 10.1111/j.1365-2125.2012.04167.x. View

2.
Mackenbach J, Stirbu I, Roskam A, Schaap M, Menvielle G, Leinsalu M . Socioeconomic inequalities in health in 22 European countries. N Engl J Med. 2008; 358(23):2468-81. DOI: 10.1056/NEJMsa0707519. View

3.
Ruokoniemi P, Korhonen M, Helin-Salmivaara A, Lavikainen P, Jula A, Junnila S . Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. Br J Clin Pharmacol. 2011; 71(5):766-76. PMC: 3093082. DOI: 10.1111/j.1365-2125.2010.03895.x. View

4.
Perreault S, Dragomir A, Blais L, Berard A, Lalonde L, White M . Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009; 65(10):1013-24. DOI: 10.1007/s00228-009-0673-0. View

5.
Wei M, Ito M, Cohen J, Brinton E, Jacobson T . Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013; 7(5):472-83. DOI: 10.1016/j.jacl.2013.03.001. View